You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Harvard Business School
Moodys
McKesson

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for NRX-1074

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug NRX-1074?

NRX-1074 is an investigational drug.

There have been 13 clinical trials for NRX-1074. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2018.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Bipolar Disorder. The leading clinical trial sponsors are Naurex, Inc, NeuroRx, Inc., and Target Health Inc.

There is one US patent protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for NRX-1074
TitleSponsorPhase
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar DepressionBracket, Inc.Phase 3
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar DepressionStats CollaborativePhase 3
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar DepressionTarget Health Inc.Phase 3

See all NRX-1074 clinical trials

Clinical Trial Summary for NRX-1074

Top disease conditions for NRX-1074
Top clinical trial sponsors for NRX-1074

See all NRX-1074 clinical trials

International Patents for NRX-1074

Drugname Country Document Number Estimated Expiration Related US Patent
NRX-1074 Australia 2011215704 2030-02-11   Start Trial
NRX-1074 Australia 2012328927 2030-02-11   Start Trial
NRX-1074 Australia 2017213587 2030-02-11   Start Trial
NRX-1074 Australia 2019204073 2030-02-11   Start Trial
NRX-1074 Brazil 112014009851 2030-02-11   Start Trial
NRX-1074 Canada 2789331 2030-02-11   Start Trial
NRX-1074 Canada 2853364 2030-02-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Harvard Business School
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.